Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Gilead’s Jyseleca (filgotinib) Receives the MHLW’s Approval for Rheumatoid Arthritis

Shots: The approval is based on two clinical trials (P-III FINCH and P-II DARWIN) programs assessing Jyseleca in 3,500+ patients across a range of RA patient populations, including patients new to treatment and those who have demonstrated inadequate response to treatment with SOC including biologic DMARDs. Gilead and Eisai will jointly commercialize Jyseleca across Japan […]Read More

Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with

Shots: Roche reports the new 2-year data from Part 1 of the FIREFISH study assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA. The 2-year results in infants treated with Evrysdi showed that continued improvement and achieve motor milestones The exploratory analysis demonstrated 88% of infants were alive and required no permanent ventilation […]Read More

PharmaShots Weekly Snapshot (Sept 21-25, 2020)

Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal Published: Sept 25,2020 | Tags: Philips, Launches, QuickClear Mechanical Thrombectomy System, Blood Clot Removal 2. BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma Published: Sept 25,2020 | Tags: BMS, Reports, Results, Opdivo, (nivolumab), P-III, CheckMate […]Read More

Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal

Shots: Royal Philips has expanded its peripheral vascular disease portfolio with the launch of the QuickClear mechanical thrombectomy system. The system features an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems The system eliminates the requirement for capital equipment or expensive accessories, […]Read More

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274

Shots: The P-III CheckMate -274 study involves assessing of Opdivo vs PBO in 709 patients in a ratio (1:1) with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery for up to 1yr. The study met its 1EPs of DFS in both all randomized patients and in patients whose tumor cells express […]Read More

Novavax Initiates P-III Study of its COVID-19 Vaccine in the

Shots: Novavax has initiated a P-III study assessing the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in Matrix-M in up to 10,000 individuals aged 18-84yrs. with/out relevant comorbidities, over the next 4-6wks. Half the participants will receive two IM injections of a vaccine comprising 5µg of protein antigen with 50µg Matrix‑M adjuvant, administered 21 […]Read More

Accord Launches Zercepac (biosimilar, trastuzumab) in the UK

Shots: Accord launches Zercepac as s a biosimilar referencing Herceptin in the UK, following the EC’s approval in Jul’2020. The EC’s approval is based on a series of robust studies including comparative quality studies, pre/ clinical studies. The results confirmed the Zercepac’s bio-similarity, demonstrating comparable efficacy and safety to the Herceptin Zercepac is the first […]Read More

Top 20 Oncology Companies by Total Products

To remain successful in the oncology market, change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However, despite robust levels of pipeline activity, oncology remains a challenging area for research […]Read More